Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

NCT05000294 is registered in ClinicalTrials.gov with University of Florida as lead sponsor.

NCT NCT05000294
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05000294 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
Lead sponsor
University of Florida
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 7, 2021
Completion date
June 30, 2027
Enrollment
29 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bile duct cancer, breast cancer, gall bladder cancer, neuroendocrine tumors, ovarian cancer, pancreatic adenocarcinoma, prostate cancer, soft tissue sarcoma, vulvar cancer